These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 23565471)
1. Diabetes mellitus in the young: Gliptins or sulfonylurea after metformin? Muthukrishnan J; Dawra S; Marwaha V; Bishnoi JS; Narayanan CS Indian J Endocrinol Metab; 2012 Dec; 16(Suppl 2):S474-6. PubMed ID: 23565471 [TBL] [Abstract][Full Text] [Related]
2. Comparative Evaluation of Safety and Efficacy of Glimepiride and Sitagliptin in Combination with Metformin in Patients with Type 2 Diabetes Mellitus: Indian Multicentric Randomized Trial - START Study. Devarajan TV; Venkataraman S; Kandasamy N; Oomman A; Boorugu HK; Karuppiah SKP; Balat D Indian J Endocrinol Metab; 2017; 21(5):745-750. PubMed ID: 28989886 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P; Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236 [TBL] [Abstract][Full Text] [Related]
4. Sitagliptin 100 mg vs glimepiride 1-3 mg as an add-on to insulin and metformin in type 2 diabetes (SWIM). Kesavadev J; Pillai PBS; Shankar A; Krishnan G; Jothydev S Endocr Connect; 2017 Nov; 6(8):748-757. PubMed ID: 28982699 [TBL] [Abstract][Full Text] [Related]
5. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone. Srivastava S; Saxena GN; Keshwani P; Gupta R J Assoc Physicians India; 2012 Mar; 60():27-30. PubMed ID: 22799111 [TBL] [Abstract][Full Text] [Related]
6. Optimal candidates for the switch from glimepiride to sitagliptin to reduce hypoglycemia in patients with type 2 diabetes mellitus. Kim HM; Lim JS; Lee BW; Kang ES; Lee HC; Cha BS Endocrinol Metab (Seoul); 2015 Mar; 30(1):84-91. PubMed ID: 25325279 [TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy of sitagliptin as either monotherapy or add-on therapy to metformin: improvement in glycemic control over 2 years in patients with type 2 diabetes. Katzeff HL; Williams-Herman D; Xu L; Golm GT; Wang H; Dong Q; Johnson JR; O'Neill EA; Kaufman KD; Engel SS; Goldstein BJ Curr Med Res Opin; 2015 Jun; 31(6):1071-7. PubMed ID: 25850968 [TBL] [Abstract][Full Text] [Related]
8. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of sitagliptin when added to ongoing therapy in korean subjects with type 2 diabetes mellitus. Chung HS; Lee MK Diabetes Metab J; 2011 Aug; 35(4):411-7. PubMed ID: 21977462 [TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of efficacy and safety of combination of metformin-vidagliptin versus metfromin-glimepiride in most frequently used doses in patients of type 2 diabetes mellitus with inadequately controlled metformin monotherapy-A randomised open label study. Gupta S; Khajuria V; Tandon VR; Mahajan A; Gillani ZH Perspect Clin Res; 2015; 6(3):163-8. PubMed ID: 26229753 [TBL] [Abstract][Full Text] [Related]
11. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594 [TBL] [Abstract][Full Text] [Related]
12. A pharmacoeconomic analysis to compare cost-effectiveness of metformin plus teneligliptin with metformin plus glimepiride in patients of type-2 diabetes mellitus. Tandon T; Dubey AK; Srivastava S; Manocha S; Arora E; Hasan N J Family Med Prim Care; 2019 Mar; 8(3):955-959. PubMed ID: 31041232 [TBL] [Abstract][Full Text] [Related]
13. Effects of Sitagliptin on Pancreatic Beta-Cells in Type 2 Diabetes With Sulfonylurea Treatment: A Prospective Randomized Study. Sato A; Takei M; Hiramatsu K; Takeda T; Miyamoto T; Yamazaki M; Sato Y; Komatsu M J Clin Med Res; 2019 Jan; 11(1):15-20. PubMed ID: 30627273 [TBL] [Abstract][Full Text] [Related]
14. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Kasichayanula S; Liu X; Shyu WC; Zhang W; Pfister M; Griffen SC; Li T; LaCreta FP; Boulton DW Diabetes Obes Metab; 2011 Jan; 13(1):47-54. PubMed ID: 21114603 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V; Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140 [TBL] [Abstract][Full Text] [Related]
16. Combination Therapy with a Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Metformin Markedly Improves HbA1c Levels in Japanese Patients with Type 2 Diabetes Mellitus. Hirao K; Maeda H; Shirabe S; Yamamoto R; Hirao T; Hirao S; Yamauchi M; Arai K Jpn Clin Med; 2012; 3():1-7. PubMed ID: 23946679 [TBL] [Abstract][Full Text] [Related]
17. Real-World Clinical Effectiveness and Tolerability of Hydroxychloroquine 400 Mg in Uncontrolled Type 2 Diabetes Subjects who are not Willing to Initiate Insulin Therapy (HYQ-Real-World Study). Gupta A Curr Diabetes Rev; 2019; 15(6):510-519. PubMed ID: 31713476 [TBL] [Abstract][Full Text] [Related]
18. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Umpierrez G; Issa M; Vlajnic A Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436 [TBL] [Abstract][Full Text] [Related]
19. Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy. Rigby SP; Handelsman Y; Lai YL; Abby SL; Tao B; Jones MR Endocr Pract; 2010; 16(1):53-63. PubMed ID: 19789153 [TBL] [Abstract][Full Text] [Related]